Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Bendamustine, and Nivolumab in R/R Classical Hodgkin Lymphoma
NCT03739619Phase 2Completed
- Sponsor
- Emory University
- Start
- Nov 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose at 42 days and Complete Response Rate at 2 years. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03739619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739619.